SPOTLIGHT: GPC hit by high R&D costs


Germany's GPC Biotech announced wider losses as a result of the expense of developing its prostate cancer therapy Satraplatin. A recent delay in gaining FDA approval of the drug sent GPC shares tumbling. Release